Salvia Therapeutics

News

Salvia raises 26 million euros to finance migraine neurostim...

Salvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation therapy for chronic migraine.

News

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks